Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review
Fingerprint
Entra nei temi di ricerca di 'Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication'. Insieme formano una fingerprint unica.